Targeted metabolomic evaluation of peripheral blood mononucleated cells from patients with PMM2-CDG

Phosphomannomutase-2 (PMM2) deficiency represents the most common congenital disorder of glycosylation (CDG). Currently, little is known about cell metabolic alterations occurring in these patients. Here, we quantified compounds connected to protein glycosylation (GDP-mannose, UDP-derivatives), energy metabolism (high-energy phosphates, nicotinic coenzymes, oxypurines), oxidative/nitrosative stress (GSH, nitrite, nitrate) and free amino acids in extracts of peripheral blood mononucleated cells (PBMCs), of seven PMM2-CDG patients and ten control healthy donors. Besides marked GDP-mannose decrease, PBMCs of PMM2-CDG patients had higher UDP-glucose (UDP-Glc), UDP-galactose (UDP-Gal) and UDP-Glucuronic levels, lower ATP, GTP and UTP levels, abnormal ATP/ADP, ATP/AMP and NAD<sup>+</sup>/NADH ratios, increased xanthine, uric acid and nitrite + nitrate levels, and decreased GSH and free amino acids concentrations. These results suggest a new, conceivable metabolic route leading to the increase of specific UDP-derivatives (UDP-Glc, UDP-Gal and UDP-Glucuronic), also potentially explaining the glycogen abnormalities recently found in PMM2-CDG patients. Altogether, this study highlighted various metabolic changes caused by PMM2 deficiency, illustrating the widespread effects of PMM2 mutations (beyond N-glycan biosynthesis) that may significantly vary depending on the cell line considered. Using PBMCs, as a cellular model of lower invasiveness than skin fibroblast, may advantage cell metabolism studies to investigate new therapies specifically targeted to PMM2 deficiency.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-05-07
DOI
https://doi.org/10.1038/s41598-025-98846-8
Citations
3
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
2.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeted metabolomic evaluation of peripheral blood mononucleated cells from patients with PMM2-CDG

Valentina Di Pietro, Andréa Graziani, Angela Maria Amorini, Alessandro Barbato et al.
3 citations
Scientific Reports
Cancer, Hypoxia, and Metabolism
2.81
article

Targeted metabolomic evaluation of peripheral blood mononucleated cells from patients with PMM2-CDG

Valentina Di Pietro, Andréa Graziani, Angela Maria Amorini, Alessandro Barbato, Giovanni Li Volti, Lara Cirnigliaro, Alessandra Pittalà, Salvatore Longo, Giovanni Tabbı̀, Rita Maria Elisa Barone, Cesarina Giallongo, Barbara Tavazzi, Daniele Tibullo, Lucia Longhitano, Giuseppe Lazzarino, Enrico La Spina, Fabio Pettinato, Renata Mangione, Miriam Wissam Saab, Giacomo Lazzarino, Alfio Distefano
article en
3 citations

Abstract

Phosphomannomutase-2 (PMM2) deficiency represents the most common congenital disorder of glycosylation (CDG). Currently, little is known about cell metabolic alterations occurring in these patients. Here, we quantified compounds connected to protein glycosylation (GDP-mannose, UDP-derivatives), energy metabolism (high-energy phosphates, nicotinic coenzymes, oxypurines), oxidative/nitrosative stress (GSH, nitrite, nitrate) and free amino acids in extracts of peripheral blood mononucleated cells (PBMCs), of seven PMM2-CDG patients and ten control healthy donors. Besides marked GDP-mannose decrease, PBMCs of PMM2-CDG patients had higher UDP-glucose (UDP-Glc), UDP-galactose (UDP-Gal) and UDP-Glucuronic levels, lower ATP, GTP and UTP levels, abnormal ATP/ADP, ATP/AMP and NAD<sup>+</sup>/NADH ratios, increased xanthine, uric acid and nitrite + nitrate levels, and decreased GSH and free amino acids concentrations. These results suggest a new, conceivable metabolic route leading to the increase of specific UDP-derivatives (UDP-Glc, UDP-Gal and UDP-Glucuronic), also potentially explaining the glycogen abnormalities recently found in PMM2-CDG patients. Altogether, this study highlighted various metabolic changes caused by PMM2 deficiency, illustrating the widespread effects of PMM2 mutations (beyond N-glycan biosynthesis) that may significantly vary depending on the cell line considered. Using PBMCs, as a cellular model of lower invasiveness than skin fibroblast, may advantage cell metabolism studies to investigate new therapies specifically targeted to PMM2 deficiency.

Scientific ReportsVol. 15(1)
University of Catania (IT), Consorzio Catania Ricerche (IT), Saint Camillus International University of Health and Medical Sciences (IT), Etna Biotech (Italy) (IT), NIHR Surgical Reconstruction and Microbiology Research Centre (GB), Institute of Crystallography (IT), University of Birmingham (GB)
Zero hunger
Openalex Percentile: Top 10%
Cancer, Hypoxia, and Metabolism
2.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.